Navigation Links
Staphylococcus aureus vaccine development on track ? safe and,immunogenic in Phase I clinicaltrials

VIENNA, Austria, May 18, 2007 – Intercell AG (VSE, “ICLL”) has been informed by its strategic partner Merck & Co., Inc. on the results of a Phase I study involving in total over 120 adult healthy volunteers comparing safety and immunogenicity of different doses of the Staphylococcus aureus vaccine.

The Staphylococcus aureus vaccine is based on a conserved protein antigen discovered by Intercell’s Antigen Identification Program (AIP®) and was licensed to Merck & Co., Inc. on an exclusive world wide basis in 2003.

The data show that the vaccine is safe and generally well tolerated. Immune responses were observed within several weeks following vaccination and these immune responses persisted throughout the course of the study.

“We are very pleased that the vaccine candidate, for which the antigen was identified by our proprietary AIP® technology, delivered promising clinical data, and look forward to its further clinical development ”, states Gerd Zettlmeissl, CEO of Intercell. “These data underline the high potential of our AIP® technology for the identification of other bacterial vaccine product candidates in?house or in collaboration with leading vaccine companies”.

About Staphylococcus aureus and nosocomial infections
Hospital?acquired infections are one of the major causes of death and serious illness worldwide,
resulting in an annual burden of more than USD 20 billion in the developed world. In the United
States alone, about two million patients become infected annually while receiving health care in
hospitals. The incidence of nosocomial infections is steadily increasing due to medical
interventions and most notably due to the emergence of antibiotic resistant bacteria circulating in
hospitals. Staphylococcus aureus is the most frequent cause of hospital acquired infections. In
addition to bloodstream infections with a mortality rate of up to 35%, infections of bone, heart and
other inner organs are leading to serious health complications, death and economic burden. Today,
approximately 50% of Staphylococcus aureus strains isolated in hospitals worldwide are resistant to
multiple antibiotics, rendering staphylococcal disease management increasingly difficult and
challenging.

About Intercell AG:
Intercell AG is a growing biotechnology company which focuses on the design and Intercell AG is
a growing biotechnology company which focuses on the design and development of novel
vaccines for the prevention and treatment of infectious diseases with substantial unmet medical
need. The Company develops antigens and adjuvants which are derived from its proprietary
technology platforms, and has in?house GMP manufacturing capability. Based on these
technologies, Intercell has strategic partnerships with a number of global pharmaceutical
companies, including Novartis, Merck & Co., Inc., Wyeth, sanofi pasteur, Kirin and the Statens
Serum Institut.

The Company’s leading product, a prophylactic vaccine against Japanese Encephalitis, successfully
concluded pivotal Phase III clinical trials in 2006. The regulatory process towards a Biologics
License Application (BLA) to the U.S. Food and Drug Administration (FDA) has been initiated.
The broad development pipeline includes a Pseudomonas vaccine in Phase II, a therapeutic
vaccine for Hepatitis C in Phase II, partnered vaccines for Tuberculosis and Staphylococcus aureus
which are in Phase I, and five products focused on infectious diseases in preclinical development.
Intercell is listed on the Vienna stock exchange under the symbol “ICLL”.

For more information please visit: www.intercell.com
Contact Interce ll AG:
Intercell AG
Katharina Wieser
Head of Corporate Communications
Campus Vienna Biocenter 2, A?1030 Vienna
P: +43?1?20620?303 Mail to: kwieser@intercell.com

'"/>




Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine
3. Apollo develops needle-free topical vaccine
4. Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology:
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
Breaking Medicine News(10 mins):